{
    "clinical_study": {
        "@rank": "42034", 
        "acronym": "BKM120", 
        "arm_group": {
            "arm_group_label": "BKM120 plus radiotherapy", 
            "arm_group_type": "Experimental", 
            "description": "Three cohorts of patients will be treated with escalating doses of oral BKM120. The doses will be 50mg, 80mg and 100mg, once daily. Patients will be treated with BKM120 for a total of fourteen days. One week after commencing BKM120, patients will start palliative radiotherapy treatment. Radiotherapy treatment will be delivered as 20Gy in 5 fractions over a one week period. There will be an expansion cohort at the MTD. Patients in an optional fourth cohort will take BKM120 for 4 weeks at the MTD."
        }, 
        "brief_summary": {
            "textblock": "This study will test whether a drug called BKM120 is a safe and effective treatment when\n      given to lung cancer patients having radiotherapy treatment. The trial will identify which\n      of three possible doses of BKM120 is best to give with lung radiotherapy."
        }, 
        "brief_title": "Palliative Thoracic Radiotherapy Plus BKM120", 
        "condition": "Carcinoma, Non-Small-Cell Lung", 
        "condition_browse": {
            "mesh_term": [
                "Carcinoma", 
                "Carcinoma, Non-Small-Cell Lung"
            ]
        }, 
        "detailed_description": {
            "textblock": "This study will be a single-centre, open-label, 3+3 cohort, dose escalation phase I study of\n      the use of BKM120 in combination with thoracic radiotherapy. Patients with incurable NSCLC\n      requiring palliative thoracic radiotherapy will be eligible for entry.\n\n      The first three cohorts of patients will be treated with escalating doses of BKM120. These\n      patients will be treated with BKM120 for a total of fourteen days. One week after commencing\n      BKM120, patients will start palliative radiotherapy treatment. Radiotherapy treatment will\n      be delivered as 20Gy in 5 fractions over a one week period. Maximum tolerated dose (MTD)\n      will be determined and a further 6 patients will be treated at this dose. Response to BKM120\n      treatment will be based upon changes in tumour hypoxia and perfusion as detected by 18F-Miso\n      PET-CT scans and perfusion CT scans respectively.\n\n      In the event that no changes are detected in tumour hypoxia or perfusion in cohorts 1-3, an\n      optional group of patients (cohort 4) will be recruited. These patients will receive BKM120\n      treatment for a total of 28 days. Three weeks after commencing BKM120, this cohort will\n      receive palliative radiotherapy with 20Gy in 5 fractions over a one week period."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Evidence of histologically confirmed NSCLC of any stage\n\n          -  Thoracic lesion requiring palliative radiotherapy and which has been identified on a\n             scan within eight weeks of starting the trial.\n\n          -  Male or female, age \u2265 18 years at the day of consenting to the study.\n\n          -  Life expectancy of at least 16 weeks.\n\n          -  ECOG performance score of 0-1.\n\n          -  Patient is able to swallow and retain oral medication.\n\n          -  The patient is willing to provide written informed consent and is likely to comply\n             with the protocol for the duration of the study, and scheduled follow-up visits and\n             examinations.\n\n          -  Haematological and biochemical indices within the ranges shown below:\n\n               -  Haemoglobin (Hb) \u2265 9.0 g/dL\n\n               -  Absolute neutrophil count \u2265 1.5 x 109/L\n\n               -  Platelet count \u2265100 x 109/L\n\n               -  International Normalised Ratio (INR) \u2264 1.5\n\n               -  Potassium, calcium and Magnesium within normal range\n\n               -  ALT and AST within normal range or \u22643.0 times ULN if liver metastases are\n                  present\n\n               -  Total serum bilirubin within normal range, or \u22641.5 times ULN if liver metastases\n                  are present or total bilirubin \u22643.0 times ULN if the patient has well documented\n                  Gilbert's disease and absence of other contributing disease process at the time\n                  of diagnosis\n\n               -  Creatinine \u2264 1.5 x ULN\n\n               -  Fasting plasma glucose (FPG) \u2264 120mg/dL [6.7 mmol/L]\n\n        Exclusion Criteria:\n\n          -  Previous chemotherapy or biological therapy within four weeks of starting study\n             treatment.\n\n          -  Treatment with any other investigational agent, or participation in another\n             interventional clinical trial within 28 days prior to enrolment.\n\n          -  Patient has not recovered to grade 1 or better (except alopecia) from related side\n             effects of any prior antineoplastic therapy.\n\n          -  Treatment at the start of study treatment with any drugs known to be moderate or\n             strong inhibitors or inducers of isoenzyme CYP3A4, and the treatment cannot be\n             discontinued or switched to a different medication prior to starting study drug.\n\n          -  Presence of active uncontrolled or symptomatic CNS metastases. Patients with\n             asymptomatic CNS metastases may participate in this trial. Any prior local treatment\n             for CNS metastases must have been completed treatment \u2265 28 days prior to enrolment in\n             the trial (including surgery and radiotherapy).\n\n          -  Patient has poorly controlled diabetes mellitus (HbA1c > 8 %)\n\n          -  Previous exposure to PI3K, mTOR, or AKT inhibitor\n\n          -  Patient has a known hypersensitivity to any of the excipients of BKM120\n\n          -  Previous thoracic radiotherapy treatment\n\n          -  Any previous extra-thoracic radiotherapy within 28 days prior to enrolment\n\n          -  Medically documented history of or active major depressive episode, bipolar disorder,\n             obsessive-compulsive disorder, schizophrenia, a history of suicidal attempt or\n             ideation, or risk of doing harm to others\n\n          -  Patient meets the cut-off score of \u2265 12 in the PHQ-9 or a cut-off of \u2265 15 in the\n             GAD-7 mood scale, respectively, or selects a positive response of '1, 2, or 3' to\n             question number 9 regarding potential for suicidal thoughts ideation in the PHQ-9\n             (independent of the total score of the PHQ-9)\n\n          -  Patient has \u2265CTCAE grade 3 anxiety\n\n          -  Other psychological, social or medical condition, physical examination finding or a\n             laboratory abnormality that the Investigator considers would make the patient a poor\n             trial candidate or could interfere with protocol compliance or the interpretation of\n             trial results.\n\n          -  Patient has a concurrent malignancy or has had any malignancy (other than NSCLC) in\n             the last 3 years prior to start of study treatment (with the exception of adequately\n             treated basal or squamous cell carcinoma or cervical carcinoma in situ)\n\n          -  Patient has had major surgery within 14 days of starting the study drug.\n\n          -  Patient has any other concurrent severe, and/or uncontrolled medical condition that\n             would, in the investigator's judgement contraindicate patient participation in the\n             clinical study (e.g. chronic pancreatitis, chronic active hepatitis).\n\n          -  Patient has impairment of gastrointestinal (GI) function or GI disease that may\n             significantly alter the absorption of BKM120.\n\n          -  Patients who are known to be serologically positive for Hepatitis B, Hepatitis C or\n             HIV.\n\n          -  Patient has active cardiac disease or a history of myocardial infarction within 6\n             months of entering the trial, congestive heart failure ( New York Heart Association\n             functional classification III-IV) or documented cardiomyopathy\n\n          -  Pregnant or breast-feeding women, or women of childbearing potential unless effective\n             methods of contraception are used. Oral contraception, injected or implanted hormonal\n             methods are not allowed as BKM120 potentially decreases the effectiveness of hormonal\n             contraceptives.\n\n          -  Women of child-bearing potential must have a negative serum pregnancy test less than\n             72 hours prior to initiating treatment"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "30", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "April 16, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02128724", 
            "org_study_id": "OCTO_031", 
            "secondary_id": "2012-003762-40"
        }, 
        "intervention": {
            "arm_group_label": "BKM120 plus radiotherapy", 
            "description": "BKM120 is a highly specific inhibitor of phosphatidylinositol 3-kinase (PI3K). BKM120 is supplied as 10mg and 50mg hard gelatin capsules.", 
            "intervention_name": "BKM120", 
            "intervention_type": "Drug", 
            "other_name": "buparlisib"
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "Lung cancer", 
            "BKM120", 
            "Hypoxia", 
            "Misonidazole", 
            "Radiotherapy"
        ], 
        "lastchanged_date": "April 29, 2014", 
        "link": [
            {
                "description": "Information about the trial on the Oncology Clinical Trials Office (OCTO) website. OCTO run the trial on behalf of the sponsor, the University of Oxford.", 
                "url": "http://www.octo-oxford.org.uk/alltrials/trials/BKM120.html"
            }, 
            {
                "description": "Information about the trial on the Cancer Research UK (CRUK) website.", 
                "url": "http://www.cancerresearchuk.org/cancer-help/trials/a-study-looking-adding-biological-therapy-to-radiotherapy-non-small-cell-lung-cancer-bkm120"
            }
        ], 
        "location": {
            "facility": {
                "address": {
                    "city": "Oxford", 
                    "country": "United Kingdom", 
                    "state": "Oxon", 
                    "zip": "OX3 7LE"
                }, 
                "name": "Churchill Hospital"
            }, 
            "investigator": {
                "last_name": "Geoff Higgins, MRCP, FRCR, D.Phil", 
                "role": "Principal Investigator"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "United Kingdom"
        }, 
        "number_of_arms": "1", 
        "official_title": "A CR-UK Phase I Study of BKM120 in Patients With Non-small Cell Lung Cancer (NSCLC) Receiving Thoracic Radiotherapy", 
        "other_outcome": [
            {
                "description": "The levels of phospho-Akt expression in normal tissues may reflect the efficacy of BKM120. Changes in phospho-Akt expression will be monitored during the trial using PBMCs taken during the trial.\nReductions in phospho-Akt expression of PBMC's following BKM120 treatment will be correlated with changes observed with the functional imaging investigations.", 
                "measure": "Determine phosphorylation status of Akt in peripheral blood mononuclear cells (PBMCs)", 
                "safety_issue": "No", 
                "time_frame": "Baseline, days 8, 14, 28 and 56"
            }, 
            {
                "description": "Exploratory studies will aim to correlate response to BKM120 with activation of specific molecular pathways present in the archived, diagnostic, tumour biopsy sample. pAKT and PTEN levels will be assessed in the biopsy tissue.", 
                "measure": "Measure tumour pAkt and PTEN levels", 
                "safety_issue": "No", 
                "time_frame": "Archival sample taken before trial entry"
            }, 
            {
                "description": "Exploratory studies will aim to correlate response to BKM120 with activation of specific molecular pathways present in the archived, diagnostic, tumour biopsy sample. Mutation status of RAS, PI3K and EGFR will be determined by PCR in the biopsy tissue.", 
                "measure": "Identify tumour mutation status of RAS, PI3K and EGFR by PCR", 
                "safety_issue": "No", 
                "time_frame": "Archival sample taken before trial entry"
            }
        ], 
        "overall_contact": {
            "email": "EarlyPhaseTrials@octo-oxford.org.uk", 
            "last_name": "Naomi McGregor", 
            "phone": "+44 1865 227192"
        }, 
        "overall_contact_backup": {
            "email": "EarlyPhaseTrials@octo-oxford.org.uk", 
            "last_name": "Joanne Hale", 
            "phone": "+44 1865 227197"
        }, 
        "overall_official": {
            "affiliation": "University of Oxford", 
            "last_name": "Geoff Higgins, MRCP, FRCR, D.Phil", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United Kingdom: Medicines and Healthcare Products Regulatory Agency", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "November 2016", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "The MTD is defined as the highest dose at which no more than 1 of 6 patients or 0 of 3 patients experience a dose limiting toxicity (DLT).\nDLTs will be defined per NCI CTCAE v 4.0. The following will be considered DLT if they occur at any point whilst the patient is on study: 1) \u2265 Any grade 3 non-haematological toxicity of any duration, with the exception that nausea, vomiting or diarrhoea will be considered DLT only if any of them persist for >48 hours despite maximum supportive care. 2) \u2265Grade 4 haematological toxicity. 3) Mood deterioration from baseline. DLT will be any grade \u22653 mood change if BL score of 2. DLT will be any grade \u22652 mood change if baseline score of \u2264 1.", 
            "measure": "To determine the MTD of BKM120 when administered concomitantly with thoracic radiotherapy  in patients with incurable NSCLC", 
            "safety_issue": "Yes", 
            "time_frame": "8 weeks (10 weeks cohort 4)"
        }, 
        "reference": {
            "PMID": "22108822", 
            "citation": "Fokas E, Im JH, Hill S, Yameen S, Stratford M, Beech J, Hackl W, Maira SM, Bernhard EJ, McKenna WG, Muschel RJ. Dual inhibition of the PI3K/mTOR pathway increases tumor radiosensitivity by normalizing tumor vasculature. Cancer Res. 2012 Jan 1;72(1):239-48. doi: 10.1158/0008-5472.CAN-11-2263. Epub 2011 Nov 22."
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02128724"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "18F-Miso is a radiotracer that selectively accumulates in hypoxic tissues. 18F-Miso PET-CT scans are able to non-invasively image tumour hypoxia. A 18F-Miso PET-CT scan will be conducted prior to commencing BKM120 and repeated prior to commencing radiotherapy treatment to identify changes in tumour hypoxia due to BKM120 treatment.", 
                "measure": "Changes in 18F-Misonidazole uptake as detected by PET-CT scans", 
                "safety_issue": "No", 
                "time_frame": "Days -1 and 8"
            }, 
            {
                "description": "Perfusion CT is a technique used to study the vasculature within tumours and other tissues. It is non-invasive and readily incorporated into existing CT protocols using conventional contrast agents. A perfusion CT scan will be conducted prior to commencing BKM120 and repeated prior to commencing radiotherapy treatment to identify changes in tumour physiology due to BKM120 treatment.", 
                "measure": "Changes in blood flow as detected by perfusion CT", 
                "safety_issue": "No", 
                "time_frame": "Days -1 and 8"
            }
        ], 
        "source": "University of Oxford", 
        "sponsors": {
            "collaborator": [
                {
                    "agency": "Cancer Research UK", 
                    "agency_class": "Other"
                }, 
                {
                    "agency": "Novartis", 
                    "agency_class": "Industry"
                }
            ], 
            "lead_sponsor": {
                "agency": "University of Oxford", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "April 2013", 
        "study_design": "Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "April 2014"
    }
}